FTFatemeh Vashahi Torfi

Fatemeh Vashahi Torfi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fatemeh Vashahi Torfi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of demographic characteristics with mental anxiety caused by the spread of the COVID-19 pandemic in candidate patients for cataract surgery

    by Jamshid Eslami, Giti Setoodeh, Elahe Zaremoghadam, Fatemeh Vashahi Torfi, Reyhaneh Sadeghian, Mohamad Khaledi, Hanieh Molaee, Najmeh Parsai

    Introduction: The increasing outbreak of COVID-19 disease has challenged global public health and caused a pathological fear of its contracting. The unknown origin of COVID-19, long incubation period, high death rate, rapid transmissions, and the lack of definitive or preventive treatment caused great fear and anxiety among the world population. Objectives: This study aimed to evaluate the correlation between demographic characteristics and mental anxiety caused by the COVID-19 pandemic among candidate patients for cataract surgery. Patients and Methods: This descriptive-analytical study selected 258 candidates for cataract surgery patients referred to Shahid Dastgheib and Khalili hospitals in Shiraz. The data were collected using a demographic and the Corona Disease Anxiety Scale questionnaire. Analytical tests were used for data analysis, including Mann-Whitney U, Spearman’s correlation, Kruskal-Wallis, and univariate and multivariate linear regression. Results: Most participants were women with a mean age of 62.8 ± 15.9 years. There was no statistically significant correlation between age, education level, and history of COVID-19 with mental anxiety (P > 0.001). In contrast, gender and job indicated a statistically significant correlation. Housewives and retired people experienced higher levels of mental anxiety (P < 0.001). Multivariate linear regression explored that amongst all demographic characteristics, only female gender was an independent risk factor for patients’ mental anxiety. Conclusion: Considering the mental health of patients applying for surgery by gender status during the COVID-19 pandemic is very important.

  • Open Access

    The effect of cinacalcet on hypercalcemia in kidney transplant patients with hyperparathyroidism: systematic review and meta-analysis

    by Hanie Fooladi, Fatemeh Vashahi Torfi, Ali Khodaparast, Sara Abbasian, Noorbakhsh Alivand, Mohamad Khaledi, Soleyman Alivand, Farshad Gharebakhshi, Moein Shakerian

    Introduction: Following renal transplantation, patients with end-stage renal disease develop parathyroid dysfunction and electrolyte abnormalities, including calcium and phosphate levels. However, cinacalcet is one of the most used medications for hypercalcemia. Therefore, the present systematic review and meta-analysis aimed to investigate the effect of cinacalcet administration on hypercalcemia in patients with renal transplantation. Materials and Methods: The online databases of Cochrane, Web of Science, Scopus, and PubMed were searched until April 2023 using validated keywords. Moreover, PRISMA was used for qualitatively evaluating the studies since the study protocol was registered on the PROSPERO website. In addition, data analysis was conducted using Stata version 14, and the significance level was set at 0.05. Results: The present meta-analysis included 26 studies (24 cohort studies and two randomized clinical trials) investigating 602 patients with renal transplantation and hyperparathyroidism. According to our findings, cinacalcet reduced the serum calcium (MD: -2.24, 95% CI: -2.82, -1.67), parathormone (SMD: -0.85, 95% CI: -1.15, -0.54), and alkaline phosphatase levels (SMD: -0.45, 95% CI: -0.91, -0.01). Moreover, 30-60 mg of cinacalcet per day effectively treated hypercalcemia (SMD: -2.77, 95% CI: -3.57, -1.98), while other doses were not significantly effective. Furthermore, the effect of cinacalcet was investigated in patients using the medication for less than six months (SMD: -2.55, 95% CI: -4.25, -0.86), 12-18 months (SMD: -2.60, 95% CI: -3.53, -1.67), and more than 24 months (SMD: -1.71, 95% CI: -2.54, -0.88). Finally, the effect of cinacalcet was the highest in the patients who were 60-64 years old compared to other age groups (SMD: -3.59, 95% CI: -5.14, -2.04). Conclusion: Cinacalcet could improve hypercalcemia and hyperparathyroidism in patients with renal transplantation. Moreover, the effect of cinacalcet had a direct and positive relationship with the patient’s age. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42023428620) and Research Registry (UIN: reviewregistry1667) website.